SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 4366.
  • 2
    Balch CM,Soong SJ,Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004; 54: 131149.
  • 3
    Balch CM,Buzaid AC,Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 36353648.
  • 4
    Kirkwood JM,Strawderman MH,Ernstoff MS,Smith TJ,Borden EC,Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14: 717.
  • 5
    Kirkwood JM,Ibrahim JG,Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000; 18: 24442458.
  • 6
    Kirkwood JM,Ibrahim JG,Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001; 19: 23702380.
  • 7
    Kirkwood JM,Manola J,Ibrahim J,Sondak V,Ernstoff MS,Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004; 10: 16701677.
  • 8
    Creagan ET,Dalton RJ,Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995; 13: 27762783.
  • 9
    Wheatley K,Ives N,Hancock B,Gore M,Eggermont A,Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003; 29: 241252.
  • 10
    Lens MB,Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol. 2002; 20: 18181825.
  • 11
    Verma S,Quirt I,McCready D,Bak K,Charette M,Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer. 2006; 106: 14311442.
  • 12
    Kilbridge KL,Cole BF,Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002; 20: 13111318.
  • 13
    Kilbridge KL,Weeks JC,Sober AJ, et al. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol. 2001; 19: 812823.
  • 14
    Cormier JN,Xing Y,Ding M, et al. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol. 2007; 25: 24422448.
  • 15
    Buzaid AC,Ross MI,Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997; 15: 10391051.
  • 16
    Morton DL,Wen DR,Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992; 127: 392399.
  • 17
    McMasters KM,Reintgen DS,Ross MI, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol. 2001; 19: 28512855.
  • 18
    McMasters KM,Swetter SM. Current management of melanoma: benefits of surgical staging and adjuvant therapy. J Surg Oncol. 2003; 82: 209216.
  • 19
    Cormier JN,Xing Y,Ding M, et al. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol. 2005; 23: 60546062.
  • 20
    Morton DL,Thompson JF,Cochran AJ,Essner R,Elashoff R. Interim results of the multicenter selective lymphadenectomy trial (MSLR-I) in clinical stage I melanoma. Presented at the American Society of Clinical Oncology Annual Meeting, Orlando, FL, May 13–17, 2005.
  • 21
    Morton DL,Hoon DS,Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003; 238: 538549; discussion 549–550.
  • 22
    Gershenwald JE,Thompson W,Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999; 17: 976983.
  • 23
    Balch CM,Soong SJ,Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19: 36223634.
  • 24
    Melanoma of the skin. In: GreeneFL,PageDL,FlemingID, et al., eds. AJCC cancer staging manual.6th ed. New York: Springer; 2002: 239.
  • 25
    Eggermont AM. The role of interferon-alpha in malignant melanoma remains to be defined. Eur J Cancer. 2001; 37: 21472153.